Watchlist

Watchlist
Aerie Pharmaceuticals, Inc. (AERI)
Aerie Pharmaceuticals, Inc. (AERI)
Biotech drug pricing should not get substantially worse next year - Mizuho
In an interview with Bloomberg News, Mizuho Securities' Salim Syed says pricing in the biotech sector is "not getting any better" but "will not get substantially worse" in 2018. He says pricing and M&A activity will be key areas next year and beyond after a slowdown in deals this year. …
Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Heather Johnson as Region…
Aerie Pharmaceuticals Announces Appointment of Paul Bae as Vice President of Human Resources
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Paul Bae as Vice Presiden…
Aerie Pharmaceuticals Announces Appointment of Nhi Ong as Director of Analytics
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Nhi Ong as Director of An…
Tracking David Tepper's Appaloosa Management Portfolio - Q3 2017 Update
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper's US stock portfolio on a quarterly basis. It is based on Appaloosa Management's regulatory 13F Form filed on 11/14/2017. Please visit our Tracking David Tepper's Appaloosa Management Port…
Your Daily Pharma Scoop: Gilead CAR-T Potential, Egalet Surges, Aerie Launches Mid-Stage Study
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Gilead Sciences Today we will discuss…
Aerie Pharma launches mid-stage study of Rhopressa to support marketing application in Japan
Aerie Pharmaceuticals (NASDAQ: AERI ) initiates a U.S.-based Phase 2 clinical trial assessing eye drop Rhopressa (netarsudil ophthalmic solution) 0.02% in Japanese and Japanese-American patients. The primary objectives are to assess the non-inferiority of ocular hypotensive activity of two…
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial Designed to Meet Requirements of Regulatory Filing in Japan
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced the co…
Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Neurocrine Biosciences Today we will d…
Aerie Pharmaceuticals' (AERI) CEO Vicente Anido on Q3 2017 Results - Earnings Call Transcript
Aerie Pharmaceuticals, Inc. (AERI) Q3 2017 Earnings Conference Call November 8, 2017 05:00 PM ET Executives Richard Rubino - CFO Vicente Anido, Jr. - Chairman and CEO Thomas Mitro - President and COO Analysts Annabel Samimy - Stifel Tyler Van Buren - Cowen & Company …
Aerie Pharma Q3 net loss widens 36%; preparations for Rhopressa launch near completion; shares up 1% after hours
Aerie Pharmaceuticals (NASDAQ: AERI ) Q3 results ($M): Operating Expenses: 32.2 (+38.2%); Net Loss: (32.4) (-36.1%); Loss/Share: (0.89) (-9.9%). More news on: Aerie Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more …
Aerie Pharmaceuticals, Inc. (AERI)